Research Product

US Equity Allocation Model

Two systematic strategies on a shared regime-conditional research framework anchored on the Fama-French factor literature and a macro-stress overlay. The strategies hedge opposite ends of the megacap-concentration regime cycle: Core + Momentum Overlay on cap-weighted S&P 500 with a factor overlay, and Anti-Concentration on equal-weight S&P 500 with a dynamic top-7 megacap overlay.

SPY core (70%) with a rotating factor overlay (MTUM default, USMV defensive). Standard core-equity exposure with a momentum-tilt overlay seeking alpha against a four-factor blend benchmark.

DEFAULT36months in state
3/3 clear triggers·Next rebalance Jun 30, 2026
Last state change
Never (since inception)
Signal date
May 31, 2026 · Current
Historical context: 1st-longest of 1 DEFAULT streaks (longest on record: 36mo)
Estimated annual turnover

~9–15% of the portfolio per year (30–50% on the 30% overlay; the 70% core never trades).

Estimated tax drag, assuming the top US federal marginal rate: ~15–30 bps/yr on a whole-portfolio basis — a conservative upper bound; less at lower rates. Registered / tax-deferred accounts (RRSP, TFSA, IRA, foundation) see none. See Limitations for the full breakdown.

In brief
  • What changedNo change this month — DEFAULT held for 36 months.
  • What it meansHolding 70% SPY core + 30% MTUM (default overlay).
  • What to watchAll defensive triggers clear. Next rebalance Jun 30, 2026.
This week
Loading this week’s briefing…
Last 12 months
DEFAULTDEFENSIVE
Jun '25
DEFAULT
MTUM
Jul '25
DEFAULT
MTUM
Aug '25
DEFAULT
MTUM
Sep '25
DEFAULT
MTUM
Oct '25
DEFAULT
MTUM
Nov '25
DEFAULT
MTUM
Dec '25
DEFAULT
MTUM
Jan '26
DEFAULT
MTUM
Feb '26
DEFAULT
MTUM
Mar '26
DEFAULT
MTUM
Apr '26
DEFAULT
MTUM
May '26
DEFAULT
MTUM
Act on this signal

Vercis is the institutional research brand of FolioX (Canadian sole-founder research entity, incorporation pending). All IP, signal repos and pipeline code are held by FolioX. Research is published under the non-discretionary research exemptions of the OSC (Canada) and the SEC research-publisher regime (US). Not personalized investment advice; consult a qualified financial advisor before making any investment decisions.

Privacy · Terms of use · Disclosures